# OnCo record inflammatory-myofibroblastic-tumour (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/inflammatory-myofibroblastic-tumour/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "inflammatory-myofibroblastic-tumour" ;
  schema:name "Inflammatory myofibroblastic tumour (IMT)"@en ;
  schema:alternateName "IMT"@en, "Pulmonary inflammatory myofibroblastic tumour"@en, "Inflammatory pseudotumour"@en, "Epithelioid inflammatory myofibroblastic sarcoma"@en ;
  schema:description "IMT is a rare tumour, grouped with the sarcomas, of spindle cells mixed with inflammatory cells, most often in the lung or abdomen of children and young adults. Surgery cures most, and about half carry an ALK gene fusion, so the ALK-blocking pill crizotinib is approved for those that cannot be removed, one of the first targeted approvals for a childhood solid tumour."@en ;
  schema:url <https://onco.cc/cancers/inflammatory-myofibroblastic-tumour/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Inflammatory_myofibroblastic_tumour> ;
  schema:citation <https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-soft-tissue-treatment-pdq>, <https://web.archive.org/web/20260213082319/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor>, <https://doi.org/10.1016/S2213-2600(18)30116-4> ;
  onco:tag "nci-coverage", "rare", "sarcoma", "paediatric" ;
  onco:related <https://onco.cc/cancers/gist/>, <https://onco.cc/cancers/dermatofibrosarcoma-protuberans/>, <https://onco.cc/cancers/desmoid-tumour/>, <https://onco.cc/cancers/tenosynovial-giant-cell-tumour/>, <https://onco.cc/cancers/pecoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/technologies/rna-seq/> ;
  onco:targets <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/pdgfra/>, <https://onco.cc/targets/ret/> ;
  onco:drugs <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/ceritinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/imatinib/> ;
  onco:companies <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/childrens-oncology-group/>, <https://onco.cc/companies/curie-nki-eortc/> ;
  onco:pathways <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/race-for-children-act/>, <https://onco.cc/terms/rare-cancers/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-schoffski-lancet-respir-med/> ;
  onco:pipeline <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/repotrectinib/> ;
  onco:standardOfCare <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/ceritinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/repotrectinib/> .